Innocan Pharma Corporation: Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study
Innocan Pharma Corporation: Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study Company" or " Innocan"), is pleased to announce today that a recent study conducted in mice based on Innocan's licensed CBD-loaded liposome platform technology (LPT) for injectable CDB solutions demonstrated a prolonged release of cannabidiol (CBD) into the mice's' bloodstream for at least 50 days following two injections. This study was led by Dr. Ahuva Cern, a senior researcher in the lab of Prof. Barenholz of The Hebrew University of Jerusalem. These resul...
Source: finanznachrichten.de